公开(公告)号：AU2018309043A1

公开(公告)日：2020-02-27

申请号：AU2018309043

申请日：2018-08-02

Applicant: VERTEX PHARMA

Inventor： ANGELL PAUL T ,  LEWANDOWSKI BERENICE ,  LITTLER BENJAMIN J ,  NUGENT WILLIAM A ,  SMITH DAVID ,  STUDLEY JOHN ,  HUGHES ROBERT M

IPC: C07D207/06 ,  C07D207/263

Abstract: Processes for preparing 5,5-dimethyl-3-methylenepyrrolidin-2-one, (S)-3,5,5-trimethylpyrrolidine-2-one, (R)-3,5,5-trimethylpyrrolidine-2-one, (S)-2,4,4-trimethylpyrrolidine, and (R)-2,4,4-trimethylpyrrolidine, and their salt forms are disclosed.

公开(公告)号：AU2014349010B2

公开(公告)日：2020-01-30

申请号：AU2014349010

申请日：2014-10-31

Applicant: VERTEX PHARMA

Inventor： SWINNEY KELLY ANN ,  HURTER PATRICIA NELL ,  NADIG DAVID E ,  SMITH DAVID ,  THOMAS VANCE HAYDEN ,  WARMAN MARTIN PAUL

IPC: A61K31/435 ,  A61K31/44 ,  A61K31/47 ,  A61P43/00

Abstract: Processes of preparing pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of administering, and kits thereof are disclosed.